Tower Research Capital LLC (Trc) Pharvaris N.V. Transaction History

Tower Research Capital LLC (Trc)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$1.98 - $11.46 $18,875 - $109,248	9,533 Added 275.52%	12,993 $146,000
Q3 2022 Nov 10, 2022	BUY	$7.67 - $25.8 $26,538 - $89,268	3,460 New	3,460 $26,000
Q2 2022 Aug 15, 2022	SELL	$16.35 - $27.5 $1,258 - $2,117	-77 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$15.98 - $19.65 $1,230 - $1,513	77 New	77 $1,000
Q4 2021 Feb 14, 2022	SELL	$13.28 - $18.0 $2,802 - $3,798	-211 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.14 - $20.97 $4,599 - $7,339	-350 Reduced 62.39%	211 $4,000
Q2 2021 Aug 16, 2021	BUY	$18.05 - $29.59 $10,126 - $16,599	561 New	561 $11,000

39.6M

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $625M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.